Participated · Seed · Aug 2026

Soctera develops semiconductor-level power amplifiers intended to extend range, improve signal fidelity, and reduce thermal failure in defense, space, and commercial communications systems. The company says it co-optimizes the semiconductor stack electrically and thermally to reduce gallium nitride (GaN) content by 20X and to halve thermal resistance in each device. Soctera spun out of Cornell University's Jena-Xing research group and is based in Ithaca, N.Y. Financially, the company has secured over $4.2 million in non-dilutive government and CHIPS Act grants and completed a $4 million seed equity raise in August 2026. The seed funds are earmarked to scale the team and manufacturing and to turn the materials-level advantages into qualified power amplifiers for customers. Leadership highlights demand from next-generation radar and satellite builders as a market driver for the company’s near-term commercialization efforts.

Participated · Series A · May 2026

Kanvas Biosciences develops a spatial biology platform for microbiome drug screening, discovery and manufacturing aimed at accelerating live biotherapeutics development. The company’s lead program is KAN-001, an immuno-oncology candidate for which the recent Series A will fund clinical trials. Kanvas intends to use proceeds to advance commercial partnerships alongside clinical development. Its core technology was initially developed at Cornell University and is exclusively licensed. The company is led by CEO Matthew Cheng. The articles do not report revenue, user metrics, founding year, or prior financing details.